The International Tinnitus Journal


rolex replica

replica watches
melbet güncel

The International Tinnitus Journal

Official Journal of the Neurootological and Equilibriometric Society
Official Journal of the Brazil Federal District Otorhinolaryngologist Society

*Type a word

ISSN: 0946-5448


GABAA - Benzodiazepine-Chloride Receptor-Targeted Therapy forTinnitus Control: Preliminary Report

Author(s): Abraham Shulman Arnold M. Strashun, and Barbara A. Goldstein

Our goal was to attempt to establish neurophannacological tinnitus control (i.e., relief) with medication directed to restoration of a deficiency in the ),-aminobutyric acidbenzodiazepine- chloride receptor in tinnitus patients with a diagnosis of a predominantly central type tinnitus. Thirty tinnitus patients completed a medical audiological tinnitus patient protocol and brain magnetic resonance imaging and single-photon emission computed tomography of brain. Treatment with GABAergic and benzodiazepine medication continued for 4- 6 weeks. A maintenance dose was continued when tinnitus control was positive. Intake and outcome questionnaires were completed. Of 30 patients, 21 completed the trial (70%). Tinnitus control lasting from 4-6 weeks to 3 years was reported by 19 of the 21 (90%). The trial was not completed by 9 of the 30 (30%). No patient experienced an increase in tinnitus intensity or annoyance. Sequential brain single-photon emission computed tomography in 10 patients revealed objective evidence of increased brain perfusion. Patients with a predominantly central type tinnitus experience significant tinnitus control with medication directed to the ),-aminobutyric acid-benzodiazepine-chloride receptor.